'ABVC BioPharma Secures Japanese Patent For Its Natural MDD Treatment Candidate ABV-1504'

ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced that the Japan Patent Office has granted a new patent protection for its Major Depressive Disorder (MDD) candidate, ABV-1504. The patent, valid through 2040, strengthens ABVC's global intellectual property portfolio for PDC-1421, the active botanical ingredient in ABV-1504. The compound is now protected in four major territories as shown below:

 

Country	Patent Number / Application No.	Status	Valid Through
United States	US 11,554,154 B2	Granted	2041
Australia	2021314052	Granted	2041
Taiwan	109130285	Granted	2040
Japan	特願2023-502736	Granted	2041

 

This comprehensive patent coverage reinforces ABVC's international strategy to ultimately commercialize its botanical CNS pipeline in the most strategically important pharmaceutical markets.

Botanical Science Meets Global Market Demand

With MDD affecting over 280 million people worldwide and the global antidepressant market projected to reach $20 billion by 2030[1], ABV-1504 offers a differentiated, botanical-based alternative to traditional selective serotonin reuptake inhibitors (SSRIs). Derived from Polygala tenuifolia, the compound acts as a Norepinephrine Transporter (NET) inhibitor and has demonstrated favorable safety and efficacy in Phase II clinical studies[2]. ABV-1504 aims to provide a safer, non-addictive, and better-tolerated long-term treatment for individuals suffering from depression.